ID   COR-L23/5010
AC   CVCL_2006
DR   CLO; CLO_0002586
DR   CLDB; cl5054
DR   ECACC; 96042338
DR   Wikidata; Q54814271
RX   PubMed=7903701;
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line).
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): ECACC
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 10,11
ST   D16S539: 11,13
ST   D5S818: 10,12
ST   D7S820: 9
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 19
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1139 ! COR-L23
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 14
RX   PubMed=7903701; DOI=10.1093/jnci/86.2.110;
RA   Barrand M.A., Heppell-Parton A.C., Wright K.A., Rabbitts P.H.,
RA   Twentyman P.R.;
RT   "A 190-kilodalton protein overexpressed in
RT   non-P-glycoprotein-containing multidrug-resistant cells and its
RT   relationship to the MRP gene.";
RL   J. Natl. Cancer Inst. 86:110-117(1994).